Minority-Based CCOP at RBHS-NJ Medical School/University Hospital Cancer Center

简介（由申请人提供）：新泽西医学和牙科大学-新泽西医学院/大学医院癌症中心的少数族裔社区临床肿瘤项目成立于三年前。我们的项目服务的患者群体主要来自纽瓦克的内城社区，周边城镇和埃塞克斯县的城市社区。超过60%的患者是非裔美国人和拉丁裔美国人，他们的收入低，贫困率高，癌症死亡率高。大学医院肿瘤登记处每年记录约1000例新的癌症病例，其中头颈癌、肝癌和宫颈癌的发病率高得不成比例。我们也看到很多乳腺癌、胃肠道、前列腺癌、肺癌和脑瘤的病例。癌症中心的医生通过合作提供团队治疗方法。每个新患者都会在7个疾病特异性肿瘤委员会或大查房中的一个进行报告。癌症中心社区在与周边社区的联系方面有着卓越的记录，包括筛查和教育，流动乳腺癌和宫颈癌筛查项目以及埃塞克斯县联盟，所有这些项目都承诺招募少数民族患者参加我们的MBCCOP研究。我们已经开展了来自6个研究基地的50多个预防/控制和治疗试验，为大多数肿瘤类型以及患者在癌症或其治疗中经历的许多症状和不良事件提供了可行的方案。我们的癌症中心临床研究办公室及其工作人员在积累和维持少数民族患者的研究方面拥有丰富的经验。我们将使用来自社区的患者研究导向员来建立信任，我们将使用一种新的经irb批准的“同意助手”流程来获得非英语患者的知情同意，我们将结合外展专家的经验来教育社区中的患者有关临床试验。我们已经证明，增加的协议数量和增加的努力，以教育医生可用的临床试验增加转诊。我们概述了一个模型，该模型将确保每年有超过50名少数民族患者参加癌症控制和治疗试验。

DESCRIPTION (provided by applicant): The Minority-Based Community Clinical Oncology Program at the University of Medicine and Dentistry of New Jersey-New Jersey Medical School/University Hospital Cancer Center was established a three years ago. Our program serves a patient population which is primarily form the inner city neighborhoods of Newark, surrounding towns and urban communities of Essex County. The more than 60% of the patients are African American and Latino and have disproportionately low income, high poverty rates and high mortality from cancer. The University Hospital Tumor Registry records about 1000 new cancer cases a year, with disproportionately high incidence of head and neck, liver, and cervical cancer. We also see a high number of cases with breast, gastrointestinal, prostate, lung and brain tumors. The Cancer Center physicians work in collaboration to provide a team approach to therapy. Each new patient is presented at one of 7 disease specific tumor boards or Grand Rounds. The Cancer Center Community has an exceptional track record in outreach to the surrounding community with programs that include the screening and education, a mobile breast and cervical cancer screening program and the Essex County Coalition, all of which have pledged to recruit minority patients to our MBCCOP studies. We have opened more than 50 prevention/control and treatment trials from 6 research bases to have protocols available for most tumor types and for many of the symptoms and adverse events our patients experience from cancer or their treatment. Our Cancer Center Clinical Research Office and its staff have extensive experience with accruing and maintaining minority patients on studies. We will use patient study navigators form the community to develop trust, we will use a novel IRB-approved 'Consent Aide' process for obtaining informed consent from non-English speaking patients and we will incorporate the experience of an outreach specialist to educate patients in the community about clinical trials. We have demonstrated that increased numbers of protocols and increased efforts to educate physicians of available clinical trials increased referral. We outline a model that will ensure accrual of more than 50 minority patients a year each on cancer control and treatment trials.